Romiplostim for low platelets from leukemia treatment
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a drug called Romiplostim to help raise low platelet counts caused by leukemia treatment. It is for adults with leukemia whose platelets are below 50 and who may benefit from this therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with leukemia.
- Your platelet count is below 50 due to cancer treatment.
- You are willing to use effective birth control during the study.
- You have not had a severe blood clot or bleeding event recently.
- You are not pregnant, breastfeeding, or allergic to the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new drug called Romiplostim N01 works better than the standard drug Interleukin-11 for raising low platelet counts caused by cancer treatments like chemotherapy or radiation. If you have low platelets from your cancer therapy, you may be able to join.
This trial tests a drug called Romiplostim N01 to help platelet levels recover faster in people with blood cancers who have had a cord blood transplant. It may reduce the need for platelet transfusions and lower bleeding risk.
This trial tests a drug called romiplostim for patients whose platelet counts stay very low (below 30) for a long time after chemotherapy, even after other treatments have failed. The goal is to see if romiplostim can help raise your platelet count to a safer level.
This trial tests a drug called romiplostim to help raise platelet levels in children and young adults (ages 6–24) whose platelets drop due to chemotherapy. It’s for those with solid tumors or other non-marrow cancers who are still getting strong treatment.
This trial tests a new form of romiplostim (a drug that boosts platelets) in breast cancer patients whose platelet counts have dropped due to chemotherapy. It aims to see if it can safely raise platelet levels to reduce bleeding risk and allow chemo to continue.
This trial tests a medicine called Romiplostim N01 to help raise platelet levels in people with solid tumors who have low platelets from chemo, radiation, or immunotherapy. The goal is to see if it can safely improve platelet counts so patients can continue their cancer treatment.
Hear when a new Cancer Treatment-induced Thrombocytopenia (CTIT) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.